Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
How a "Non Traditional" background can lead to success as an MSL
Summary
In this episode, Robert Rosti shares his unique journey from medical information to becoming a Medical Science Liaison (MSL). He provides insights into the transition process, emphasizing the importance of networking and professional etiquette. Robert discusses how to leverage diverse backgrounds and offers tips for breaking into the MSL industry without prior experience. He highlights the significance of preparation, emotional intelligence, and mastering LinkedIn for effective networking. The conversation covers navigating the cultural shift from academia to industry and strategies for standing out with a nontraditional background. Robert also delves into interview techniques and the dedication required for a successful MSL career.
My guest today is Robert Rosti, Sr Medical Science Liaison at Biogen. He discusses how his "Non-Traditional" background led to great success as a Medical Science Liaison.
In this episode we discuss:
- Rob’s background
- His education and where his career began
- What made him want to transition to the industry and how did he go about it?
- How Rob landed in medical affairs and why he wanted to be an MSL?
- His advice for others who may have a non-traditional background
- What he feels is most important for ANYONE trying to transition into the industry and become an MSL?
- His advice to those that are looking to build a career in Medical Affairs
Medical Science Liaison, MSL career tips, networking in medical affairs, transitioning to industry, non-traditional background success
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
Over-Negotiation-How to Botch a Job Offer
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary